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20BACKGROUND Blood lipids are established risk factors for myocardial infarction (MI), but uncertainty persists about
the relevance of lipids, lipoprotein particles, and circulating metabolites for MI and stroke subtypes.
OBJECTIVES This study sought to investigate the associations of plasma metabolic markers with risks of incident MI,
ischemic stroke (IS), and intracerebral hemorrhage (ICH).
METHODS In a nested case-control study (912 MI, 1,146 IS, and 1,138 ICH cases, and 1,466 common control subjects) 30 to
79 years of age in China Kadoorie Biobank, nuclear magnetic resonance spectroscopy measured 225 metabolic markers in
baselineplasmasamples. Logistic regressionwasused toestimateadjustedodds ratios (ORs) fora 1-SDhighermetabolicmarker.
RESULTS Very low-, intermediate-, and low-density lipoprotein particles were positively associated with MI and IS.
High-density lipoprotein (HDL) particles were inversely associated with MI apart from small HDL. In contrast, no lipo-
protein particles were associated with ICH. Cholesterol in large HDL was inversely associated with MI and IS (OR: 0.79 and
0.88, respectively), whereas cholesterol in small HDL was not (OR: 0.99 and 1.06, respectively). Triglycerides within all
lipoproteins, including most HDL particles, were positively associated with MI, with a similar pattern for IS. Glycoprotein
acetyls, ketone bodies, glucose, and docosahexaenoic acid were associated with all 3 diseases. The 225 metabolic markers
showed concordant associations between MI and IS, but not with ICH.
CONCLUSIONS Lipoproteins and lipids showed similar associations with MI and IS, but not with ICH. Within HDL
particles, cholesterol concentrations were inversely associated, whereas triglyceride concentrations were positively
associated with MI. Glycoprotein acetyls and several non–lipid-related metabolites associated with all 3 diseases.
(J Am Coll Cardiol 2018;71:620–32) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology
Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2017.12.006
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621AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
CABG = coronary artery bypass
grafting
CHD = coronary heart disease
CI = conﬁdence interval
CKB = China Kadoorie Biobank
CVD = cardiovascular disease
HDL-C = high-density
lipoprotein cholesterol
IDL = intermediate-density
lipoprotein
IHD = ischemic heart disease
IS = ischemic stroke
LDL-C = low-density
lipoprotein cholesterol
MI = myocardial infarction
NMR = nuclear magnetic
resonance
PCI = percutaneous coronary
intervention
RCT = randomized controlled
trial
SBP = systolic blood pressure
TG = triglycerides
VLDL = very low-density
lipoproteinO bservational studies and randomizedcontrolled trials have demonstrated thatlow-density lipoprotein cholesterol (LDL-C)
is one of the most important modiﬁable and causal
risk factors for coronary heart disease (CHD) and
ischemic stroke (IS) (1–4). The relationship of LDL-C
with risk of intracerebral hemorrhage (ICH) is less
clear (4,5), and the role of other lipids (e.g., high-
density lipoprotein cholesterol [HDL-C] and triglycer-
ides [TG]) in the etiology of cardiovascular disease
(CVD) subtypes is not so well established (1).
Conventional measures of circulating lipids (e.g.,
LDL-C and HDL-C) fail to distinguish among the
size, density, or concentrations and compositions of
lipoproteins, which may have contrasting relevance
to risk of CVD (6). For example, conventional mea-
sures of HDL-C include the sum of cholesterol car-
ried in HDL particles, but ignore their composition
(including TG and phospholipids), particle size, and
subclass concentration. Likewise, the usual mea-
sures of TG reﬂect the summation of TG carried
across the various lipoproteins; just as for choles-
terol, TG may show divergent relationships with
vascular disease when transported in different li-
poprotein particles. Therefore, a more detailed
investigation of the association of individual lipo-
protein particle subclasses and lipid-related traits
with risk of CHD and stroke subtypes could be
informative.SEE PAGE 633Quantitative nuclear magnetic resonance (NMR)
metabolomics provides detailed measurements of li-
poprotein particle concentrations and their associ-
ated lipids categorized by particle size, and additional
metabolic markers (7). The approach has been used in
several population-based epidemiological and ge-
netic studies to date (6–11), but no study has yet
comprehensively investigated the associations of
these traits with different CVD subtypes in the same
study population. The present study examined the
associations of plasma lipoprotein particles and other
metabolic markers with risk of incident MI, IS, andChina (Grant Nos. 81390540, 81390541, 81390544). NMR metabolomics was s
Oxford (RE/13/1/30181). The British Heart Foundation, UK Medical Resear
funding to the Clinical Trial Service Unit and Epidemiological Studies Un
supported by the Sigrid Juselius Foundation, Finland; and works in a unit t
Medical Research Council (MC_UU_12013/1). Dr. Holmes was supported by
Biomedical Research Centre. Dr. Collins has received grants for independen
Bayer Germany, British Heart Foundation, Cancer Research UK, Medical Res
Wellcome Trust. All other authors have reported that they have no relationsh
Drs. Holmes, Millwood, and Kartsonaki contributed equally to this work and
Manuscript received September 19, 2017; revised manuscript received NoveICH in a nested case-control study within the
China Kadoorie Biobank (CKB).
METHODS
STUDY POPULATION. The CKB is a prospec-
tive cohort of 512,891 Chinese adults 30 to 79
years of age at enrollment, recruited between
2004 and 2008 from 10 (5 urban, 5 rural)
geographically deﬁned areas, as previously
described (12). For each participant, detailed
information was collected at baseline and at
periodic resurveys (5% random subset) by
questionnaire, including sociodemographic
and lifestyle (e.g., smoking, alcohol intake)
factors and medical history (including use of
certain speciﬁc medications such as statins),
and physical measurements (e.g., blood
pressure and anthropometry). Participants
provided a 10 ml nonfasting blood sample
(with time since last meal recorded) that was
separated into 1 buffy coat and 3 plasma ali-
quots. Long-term follow-up of CKB partici-
pants was achieved by electronic linkage,
using unique personal identiﬁcation
numbers, to established death and morbidity
(for cancer, CHD, stroke, and diabetes) regis-
tries and to a nationwide health insurance
system, which provides coded disease di-
agnoses (International Classiﬁcation of Diseases-10th
Revision) and procedures (e.g., coronary artery
bypass grafting, percutaneous coronary intervention)
for each episode of hospitalization. Medical records
for all hospitalizations (and a subset of all deaths) due
to vascular diseases have been reviewed systemati-
cally and independently by clinicians in Oxford and
China to minimize misclassiﬁcation.
NESTED CASE-CONTROL STUDY. A subset of 4,662
individuals was selected for the metabolomics study
from a larger nested case-control study of stroke and
CHD subtypes comprising w23,000 CKB individuals,
which included genome-wide array data and standardupported by the BHF Centre of Research Excellence,
ch Council, and Cancer Research UK provide core
it at the University of Oxford. Dr. Ala-Korpela was
hat is supported by the University of Bristol and UK
the National Institute for Health Research Oxford
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622clinical biochemistry analysis. Cases included in the
metabolomics study had an incident fatal or nonfatal
event coded as International Classiﬁcation of
Diseases-10th Revision: I21-23 for MI (n ¼ 912); I63 or
I69.3 for IS (n ¼ 1,146); and I61 or I69.1 for ICH
(n ¼ 1,138), at the censoring date of January 1, 2015,
and were selected from the youngest of the available
cases at the time of event. Common control subjects
(n ¼ 1,466) were selected from among control subjects
in the larger study and were frequency matched,
where possible, to the combined cases by age, sex,
and area. All cases and control subjects had no history
of self-reported prior doctor-diagnosed CHD, stroke,
transient ischemic attack, and cancer, and were not
using statin therapy at baseline.
MEASUREMENT OF NMR METABOLOMICS AND
CLINICAL CHEMISTRY. Baseline plasma samples
were thawed and subaliquoted at the Wolfson Labo-
ratory (University of Oxford, United Kingdom), and
100-ml aliquots were shipped on dry ice to the Brain-
shake Laboratory at Kuopio, Finland, for NMR spec-
troscopy. Of the 4,662 individuals with baseline NMR
spectroscopy measurements, 137 had measurements
conducted in duplicate. A high-throughput targeted
NMR metabolomics platform (7,11,13) was used to
generate spectra from which 225 lipid and other
metabolic measures were simultaneously quantiﬁed,
either as absolute concentrations of each metabolic
measure or as ratios. Cases and control subjects were
analyzed in random order and laboratory staff were
blinded to case or control status.
Plasma concentrations of 8 traits (total cholesterol,
LDL-C, HDL-C, TG, apolipoprotein B, apolipoprotein
A1, albumin, and creatinine) that were measured by
NMR spectroscopy were also quantiﬁed in samples
from the same 4,662 participants using standard
clinical chemistry assays at the Wolfson Laboratory
(AU 680 clinical chemistry analyzers, Beckman
Coulter [UK] Ltd., Wycombe, United Kingdom) using
manufacturers’ reagents, calibrators, and settings.
STATISTICAL ANALYSIS. To facilitate comparisons
between metabolic measures within and across as-
says, traits were standardized (i.e., values of each
metabolic marker were divided by its standard devi-
ation). We calculated Pearson’s correlation co-
efﬁcients of the 8 biochemical parameters measured
by both NMR spectroscopy and standard clinical
chemistry. The associations for traits measured by
both NMR spectroscopy and clinical chemistry with
risk of MI were assessed using logistic regression
adjusted for age (in 5-year categories), sex, fasting
time (<8 or $8 h), region (10 regions), smoking status
(never, ex-regular, occasional, current regular), andeducational attainment (no formal or primary school,
middle or high school, technical school or college or
university). Treating fasting time as a continuous trait
and adjusting the associations for both fasting time
and the square of fasting time had no material effect
on the associations. Technical replication (repeated
measurement of the same sample) was assessed
through coefﬁcients of variation, expressed as a per-
centage, for individuals that had duplicate measures
for NMR spectroscopy (n ¼ 137).
Logistic regression was used to assess the re-
lationships of all 225 metabolic measures by NMR
spectroscopy with risks of MI, IS, and ICH separately,
using the same adjustments as mentioned previously.
For each measure, adjusted odds ratios (ORs) and
95% conﬁdence intervals (CIs) per 1-SD higher
metabolic measure were estimated. In subsequent
sensitivity analyses, additional adjustments for the
associations with disease risk were made for systolic
blood pressure (SBP) and body mass index (BMI).
To account for the large number of highly
correlated metabolic measures, we used a false
discovery rate correction (14) and interpreted false
discovery rate–corrected p values <0.05 as
providing evidence against the null hypothesis. To
test the added discriminatory power of these
metabolic measures, we calculated the area under
the receiver-operating characteristic curve for 2
models: model 1 included risk factors included in
established risk prediction algorithms (age, sex,
smoking, SBP, BMI, type 2 diabetes, and total
cholesterol/HDL-C ratio) and model 2 included the
same covariates as in model 1 and in addition
included 18 principal components explaining 95% of
the variance in the 225 metabolic markers. All ana-
lyses were conducted using R version 3.3.1 (R Proj-
ect for Statistical Computing, Vienna, Austria).
RESULTS
CHARACTERISTICS OF INDIVIDUALS IN THE NESTED
CASE-CONTROL STUDY. Among the 4,662 partici-
pants with metabolomics measurements, the mean
age of stroke cases was similar to control subjects
(Table 1), but the mean age of MI cases was older
(IS 42 years of age, ICH 47 years of age, MI 52 years of
age vs. control subjects 45 years of age). Likewise, the
proportion of women among stroke cases (IS 54%; ICH
52%) was similar to that of control subjects (52%), but
the proportion was lower among MI cases (40%).
Cases had higher SBP (MI mean 141  26 mm Hg; IS
135  25 mm Hg; ICH 151  29 mm Hg) than did control
subjects (127  18 mm Hg), but levels of overall and
central adiposity, height, and physical activity were
TABLE 1 Baseline Characteristics of Participants in the Nested Case-Control Study of Vascular Disease
Control Subjects
(n ¼ 1,466)
Myocardial Infarction
(n ¼ 912)
Ischemic Stroke
(n ¼ 1,146)
Intracerebral Hemorrhage
(n ¼ 1,138)
Age and socioeconomic factors
Age, yrs 45.0  8.3 52.1  7.1 42.3  6.1 47.0  6.9
Female 52.3 39.6 54.1 52.2
College/university education 5.5 4.1 7.9 2.6
Rural residents 75.1 70.6 60.3 76.5
Lifestyle factors
Ever regular smoker 31.7 45.8 32.7 32.1
Weekly alcohol drinker 21.7 20.9 24.8 23.5
Physical activity, MET h/day 24.6  14.5 20.4  14.2 22.8  13.8 23.0  14.6
Anthropometry and blood pressure
Standing height, m 1.6  0.1 1.6  0.1 1.6  0.1 1.6  0.1
BMI, kg/m2 23.5  3.3 24.0  3.6 24.6  3.7 24.1  3.6
Waist circumference, cm 79.4  9.5 82.9  10.2 82.6  10.4 81.6  10.2
SBP, mm Hg 126.8  17.8 140.6  25.5 135.0  24.5 150.7  29.0
DBP, mm Hg 76.6  10.5 82.7  13.6 83.3  14.5 89.5  16.2
Lipids measured by clinical chemistry, mg/dl
LDL cholesterol* 84.9  27.0 92.7  30.9 88.8  27.0 84.9  27.0
HDL cholesterol 46.3  11.6 45.2  11.6 45.9  11.6 47.1  11.6
Triglycerides 177.0  150.4 194.7  177.0 185.8  150.4 177.0  150.4
Self-reported health and disease
Poor self-rated health 8.6 16.2 12.5 14.2
Diabetes 3.1 11.4 7.2 6.3
Fasting time, h 4.1  4.1 4.4  4.3 4.6  4.7 4.0  4.1
Values are mean  SD or %. *Low-density lipoprotein (LDL) cholesterol was directly measured (and not estimated using the Friedewald equation). To convert high-density
lipoprotein (HDL) cholesterol and LDL cholesterol to mmol/l, multiply by 0.0259; to convert triglycerides to mmol/l, multiply by 0.0113.
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; MET ¼ metabolic equivalent; SBP ¼ systolic blood pressure.
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623similar between cases and control subjects (Table 1).
Casesweremore likely tohave self-reporteddiabetes at
baseline (MI 11%, IS 7%, ICH 6%vs. control subjects 3%)
and poor self-rated health (MI 16%, IS 13%, ICH 14% vs.
control subjects 9%).
For clinical chemistry, MI and IS cases had
higher mean concentrations of LDL-C (MI 93 
31 mg/dl; IS 89  27 mg/dl) than did control sub-
jects (85  27 mg/dl; p < 2.8  108 comparing MI cases
with control subjects and IS cases with control
subjects), with ICH cases having similar LDL-C values
to control subjects. A similar pattern was observed for
TG. In contrast, HDL-C concentrations were broadly
similar between cases and control subjects. The
distribution of fasting times at recruitment to the
study was similar for cases and control subjects
(Table 1).
COMPARISON OF TRAITS MEASURED BY NMR
SPECTROSCOPY AND CLINICAL BIOCHEMISTRY.
Online Table 1 shows the correlation coefﬁcients of
lipids (total cholesterol, LDL-C, HDL-C, and TG),
apolipoproteins A1 and B, creatinine, and albumin as
measured by clinical chemistry and NMR spectros-
copy. There was a high correlation for LDL-C
(r ¼ 0.86) and HDL-C (r ¼ 0.88), but it wassomewhat lower for triglycerides (r ¼ 0.77). The TG
correlation did not vary by fasting status (data not
shown), and when using log transformed TG, the
correlation was higher, at 0.91. Likewise, correlation
coefﬁcients for apolipoproteins A1 and B, creatinine,
and albumin were high (0.87, 0.90, 0.98, and 0.80,
respectively). The scatterplots for these 8 traits are
presented in Online Figure 1.
The mean value for each metabolic measure, and
the corresponding coefﬁcient of variation from the
137 duplicate samples, are provided in Online Table 2.
The coefﬁcients of variation for duplicate measure-
ments on the same samples had a median value of
5.0% (interquartile range: 2.7% to 6.7%).
COMPARISONS OF ASSOCIATIONS WITH MI OF
TRAITS MEASURED BY NMR SPECTROSCOPY VERSUS
CONVENTIONAL CLINICAL CHEMISTRY. When analyzed
separately, the 8 biochemical traits measured by both
conventional chemical chemistry and NMR spectros-
copy assays indicated similar risk estimates for inci-
dent MI (Online Table 3). Positive associations with
risk of MI were observed for total cholesterol, LDL-C,
apolipoprotein B, TG, and creatinine, and inverse
associations were observed for HDL-C, apolipoprotein
A1, and albumin, for both assays.
FIGURE 1 Adjusted OR (95% CI) of MI, IS, and ICH for Lipoprotein Particle Concentration, Cholesterol, and Triglycerides as Measured by
Nuclear Magnetic Resonance Spectroscopy
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Estimates are odds ratios (ORs) per 1-SD higher metabolic marker. Models are adjusted for age, sex, fasting hours, region, smoking status, and educational
attainment. Signiﬁcance (Sig.): ***p # 0.0001, **p # 0.01, *p# 0.05, - p > 0.05 (false discovery rate [FDR]–adjusted p values). CI ¼ conﬁdence interval;
HDL ¼ high-density lipoprotein; ICH ¼ intracerebral hemorrhage; IDL ¼ intermediate-density lipoprotein; IS ¼ ischemic stroke; LDL ¼ low-density
lipoprotein; MI ¼ myocardial infarction; VLDL ¼ very low-density lipoprotein.
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FIGURE 2 Adjusted OR (95% CI) of MI, IS, and ICH for Mean Particle Diameter, Cholesterol, Triglycerides, and Apolipoproteins as
Measured by Nuclear Magnetic Resonance Spectroscopy
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Estimates are ORs per 1-SD higher metabolic marker. Models are adjusted for age, sex, fasting hours, region, smoking status, and educational
attainment. Signiﬁcance: ***p # 0.0001, **p # 0.01, *p # 0.05, - p > 0.05 (FDR-adjusted p values). ApoA1 ¼ apolipoprotein A1;
ApoB ¼ apolipoprotein B; other abbreviations as in Figure 1.
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625ASSOCIATIONS WITH LIPOPROTEIN PARTICLE AND
LIPID CONCENTRATIONS. As measured by NMR
spectroscopy, there were positive associations with
risk of MI with particle concentrations of very
low-density lipoprotein (VLDL), intermediate-density
lipoprotein (IDL), and LDL subclasses (after adjust-
ment for multiple testing), with adjusted ORs per 1 SD
increment ranging from 1.18 (95% CI: 1.07 to 1.29) for
extremely large VLDL to 1.30 (95% CI: 1.19 to 1.44) for
small VLDL. For HDL, very large (OR per SD incre-
ment: 0.87; 95% CI: 0.79 to 0.96), large (OR per SD
increment: 0.80; 95% CI: 0.73 to 0.89), and medium
(OR per SD increment: 0.86; 95% CI: 0.78 to 0.95)
subclasses were inversely associated with risk of MI,
but not small HDL (OR per SD increment: 1.01; 95% CI:
0.91 to 1.11). The estimates for cholesterol concen-
trations within individual lipoprotein subclasses werevery similar to those of the corresponding lipoprotein
particle concentrations (Figure 1).
For TG concentrations within lipoprotein sub-
classes, there were strong positive associations with
risk of MI for TG in all apolipoprotein B–containing
(VLDL, IDL, and LDL) lipoprotein particles. In
contrast to cholesterol, TG in all HDL particles other
than large HDL were positively associated with risk of
MI.
For IS, the majority of VLDL particle subclasses
were positively associated with disease risk; however,
the associations were somewhat weaker for very small
VLDL and IDL as compared with MI (e.g., OR per
SD-higher IDL: 1.10 [95% CI: 1.00 to 1.20] for IS vs. 1.19
[95% CI: 1.08 to 1.31] for MI). Particle concentrations
of large HDL were also inversely associated with IS
(OR: 0.89; 95% CI: 0.81 to 0.98), whereas small HDL
FIGURE 3 Adjusted OR (95% CI) of MI, IS, and ICH for Other Traits as Measured by NMR Spectroscopy
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Estimates are ORs per 1-SD higher metabolic marker. Models are adjusted for age, sex, fasting hours, region, smoking status, and educational
attainment. Signiﬁcance: ***p # 0.0001, **p # 0.01, *p # 0.05, - p > 0.05 (FDR-adjusted p values). Abbreviations as in Figure 1.
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626was positively associated with IS (OR: 1.12; 95% CI:
1.03 to 1.23). Likewise, the pattern of association with
IS for cholesterol concentrations within lipoprotein
particles was very similar to those for the concentra-
tions of the lipoprotein particles themselves. TG con-
centrations within most VLDL and small LDL
subclasses were also strongly positively associatedwith IS, but the associations of TG within very small
VLDL, IDL, and large or medium LDL was weaker as
compared with MI. As for MI, TG within medium and
small HDL particles were positively associated with
risk of IS.
In contrast, there were no clear associations of
concentrations of any of the lipoprotein particles or
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627their cholesterol or TG constituents with ICH
(Figure 1).
ASSOCIATIONS WITH PARTICLE DIAMETER, AND
CHOLESTEROL, TG, AND APOLIPOPROTEIN
CONCENTRATION. VLDL diameter was positively
associated with risk of MI (OR per SD: 1.13; 95% CI:
1.03 to 1.25), but LDL particle size had no association
(OR per SD: 0.99; 95% CI: 0.90 to 1.10) and HDL par-
ticle size was inversely associated with MI (OR per SD:
0.80; 95% CI: 0.73 to 0.89) (Figure 2). For IS, there
were positive associations with VLDL particle size (OR
per SD: 1.17; 95% CI: 1.07 to 1.28) and inverse associ-
ations with HDL particle size (OR per SD: 0.88;
95% CI: 0.80 to 0.96). However, in contrast to MI, LDL
particle size was inversely associated with IS (OR per
SD 0.82; 95% CI: 0.74 to 0.90). Lipoprotein particle
sizes were not associated with risk of ICH.
Remnant cholesterol concentrations (i.e., the
cholesterol in VLDL and IDL particles) (15) were
positively associated with increased risk of MI (OR per
SD: 1.27; 95% CI: 1.15 to 1.39) and IS (OR per SD: 1.20;
95% CI: 1.09 to 1.32), but not ICH (OR per SD: 1.04;
95% CI: 0.95 to 1.13). Cholesterol within HDL2 (larger
HDL particles) was strongly inversely associated with
MI (OR per SD: 0.79; 95% CI: 0.72 to 0.87), but not
with IS (OR per SD: 0.95; 95% CI: 0.86 to 1.04) or ICH
(OR per SD: 0.97; 95% CI: 0.89 to 1.05), whereas
cholesterol in HDL3 (smaller HDL particles) was not
associated with any of the vascular disease
endpoints.
TG in all measured major lipoprotein subclasses
(apolipoprotein B–containing lipoproteins and HDL)
were positively associated with higher risks of MI. In
contrast, the positive association of TG with IS was
limited to TG in VLDL. There was no association of TG
with risk of ICH.
Concentrations of apolipoprotein A1 were inversely
associated with risk of MI (OR per SD: 0.89; 95% CI:
0.81 to 0.98), but not with IS (OR per SD: 1.06; 95% CI:
0.96 to 1.16). In contrast, concentrations of apolipo-
protein B and the ratio of apolipoprotein B to apoli-
poprotein A1 were both strongly positively associated
with risk of MI (OR per SD: 1.30; 95% CI: 1.18 to 1.43;
and 1.36; 95% CI: 1.24 to 1.50, respectively) and of IS
(OR per SD: 1.25; 95% CI: 1.14 to 1.38, and 1.21; 95% CI:
1.10 to 1.33, respectively). None of the apolipopro-
teins, either individually or in ratios, was associated
with risk of ICH.
ASSOCIATIONS WITH AMINO ACIDS, FATTY ACIDS,
KETONE BODIES, GLYCOPROTEIN ACETYLS, AND
OTHER TRAITS. Among the amino acids measured,
glutamine (OR per SD increment: 0.86; 95% CI: 0.78 to
0.95) and histidine (OR per SD increment: 0.88;95% CI: 0.80 to 0.97) showed inverse associations
with MI, and isoleucine and leucine showed modest
positive associations with risk of IS. No amino acid
showed an association with ICH (Figure 3). Glucose
was positively associated with increased risk of MI
(OR per SD increment: 1.32; 95% CI: 1.18 to 1.47), IS
(OR per SD increment: 1.27; 95% CI: 1.14 to 1.42), and
ICH (OR per SD increment: 1.26; 95% CI: 1.14 to 1.40).
Among ketone bodies, b-hydroxybutyrate was asso-
ciated with MI (OR per SD increment: 1.35; 95% CI:
1.18 to 1.54), IS (OR per SD increment: 1.21; 95% CI:
1.08 to 1.36), and ICH (OR per SD increment: 1.22; 95%
CI: 1.08 to 1.36), and acetoacetate was strongly asso-
ciated with IS (OR per SD increment: 1.44; 95% CI:
1.28 to 1.61) and ICH (OR per SD increment: 1.19; 95%
CI: 1.08 to 1.32), but not with MI (OR per SD incre-
ment: 1.06; 95% CI: 0.95 to 1.18).
The inﬂammation marker, glycoprotein acetyls,
was strongly associated with all 3 vascular diseases
(for MI, OR per SD: 1.36; 95% CI: 1.22 to 1.50; for IS, OR
per SD: 1.33; 95% CI: 1.21 to 1.46; and for ICH, OR per
SD: 1.18; 95% CI: 1.08 to 1.30). There was a positive
association of creatinine with MI (OR per SD: 1.38;
95% CI: 1.09 to 1.75) and nominally with ICH (OR per
SD: 1.33; 95% CI: 1.11 to 1.59), but no association with
IS (OR per SD: 1.00; 95% CI: 0.82 to 1.22).
Among the fatty acids, using the absolute concen-
trations, many were positively associated with risks
of MI and IS. However, these ﬁndings were inﬂuenced
by circulating TG levels, and adjustment for TG
diminished all the associations for MI, whereas posi-
tive associations persisted for omega-6 fatty acids
and polyunsaturated fatty acids for IS (Online
Table 4). When reanalyzed as ratios, an inverse as-
sociation of docosahexaenoic acid (an omega-3 fatty
acid) as a proportion of total fatty acids was observed
for MI, IS, and ICH. The ratio of monounsaturated
fatty acids to total fatty acids showed a positive as-
sociation with risk of MI, whereas the ratio of satu-
rated fatty acids to total fatty acids showed an inverse
association with risk of IS.
EFFECTS OF ADDITIONAL ADJUSTMENT FOR OTHER
CARDIOVASCULAR RISK FACTORS. Further adjust-
ment for SBP and BMI attenuated the association of
lipoproteins, lipids and metabolites with risk of MI
and IS (Online Figures 2 to 10). Similarly, additional
adjustment for these factors also diminished the
associations of several traits that were associated
with ICH, particularly glycoprotein acetyls and
creatinine. Interestingly, after adjustment for SBP,
some traits such as albumin showed stronger inverse
associations with risk of MI (Online Figure 4) and an
inverse association of albumin with ICH emerged
FIGURE 4 Comparison of Adjusted OR (95% CI) of 225 Metabolic Measures as Measured by Nuclear Magnetic Resonance Spectroscopy
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Comparison between IS and (A) MI and (B) ICH. Estimates are per 1-SD higher metabolic marker. Model adjustment as in Figure 1.
Abbreviations as in Figure 1.
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628(Online Figure 10). Adjustment for SBP and BMI had
no material impact on the generally neutral associ-
ations of lipoproteins and lipid traits with risk of
ICH.
COMPARISON OF OVERALL RISK ASSOCIATIONS
FOR MI, IS, AND ICH. In analyses of all 225 traits
measured by NMR spectroscopy with disease risks,
there was general concordance of the patterns of as-
sociation between MI and IS (i.e., metabolic measures
that associated with MI tended to associate with IS;
regression slope ¼ 1.02) (Figure 4A). In contrast, there
was less of a concordance of the associations of traits
with risk of IS and ICH, with traits showing, in general,
much weaker associations with ICH (regression
slope¼0.31),with a fewnotable exceptions (Figure 4B).
DISCRIMINATORY ABILITY. Addition of 18 principal
components that explained 95% of the variance of the
225 metabolic markers into a logistic regression model
with established risk factors yielded very small, but
statistically signiﬁcant, increases in the area under
the receiver-operating characteristic curve (increases
ranged from 0.008 to 0.013) for the 3 vascular end-
points (Online Table 5).
DISCUSSION
This study provides a comprehensive examination of
the associations of lipoprotein particles, lipid con-
stituents, and multiple circulating metabolites with
risks of incident MI, IS, and ICH. The results showthat MI and IS have broadly similar strengths of as-
sociation with concentrations of lipoprotein and lipid
constituents, but for ICH the associations were sub-
stantially weaker (Central Illustration). In contrast,
certain non–lipid-related metabolites, such as glyco-
protein acetyls and glucose, showed similar strengths
of association for all 3 subtypes of CVD.
Concentrations of the apolipoprotein B–containing
lipoproteins and their cholesterol concentrations
showed positive associations with risks of MI, which
is consistent with the known causal effects of LDL-C
on risk of MI from genetic studies (16–18), and from
randomized controlled trials of LDL-C lowering ther-
apies (3,4,19). The slightly weaker association of
these lipid-related traits with risk of IS as compared
with MI is also consistent with previous studies of
conventionally measured lipids (1), and of metab-
olomics in individuals with prior vascular disease or
diabetes (20).
Importantly, the TG within all apolipoprotein B
and most HDL particles were associated with higher
risk of MI and, to a slightly lesser extent, of IS. The
positive association of TG in small and medium HDL
lipoproteins differed from the inverse association of
cholesterol in large and medium HDL lipoproteins
with MI (and IS), which raises the hypothesis that TG
and cholesterol in HDL particles have opposing re-
lationships with risk of MI or IS. This is in contrast to
the consistent associations of TG and cholesterol in
apolipoprotein B–containing lipoproteins with risk of
MI or IS.
CENTRAL ILLUSTRATION Lipoprotein Lipids and Other Metabolic Markers With Risk of Incident MI, IS, and ICH
Holmes, M.V. et al. J Am Coll Cardiol. 2018;71(6):620–32.
We assessed the associations of metabolic markers measured by nuclear magnetic resonance (NMR) spectroscopy with risk of incident myocardial infarction (MI),
ischemic stroke (IS), and intracerebral hemorrhage (ICH). The study demonstrated that lipoprotein subclasses and their lipid constituents shared associations with both
risk of MI and IS, but not with risk of ICH. For MI and IS, cholesterol (orange squares and horizontal lines) and triglycerides (green squares and horizontal lines) in
apolipoprotein B–containing lipoproteins (very low-density lipoprotein [VLDL], intermediate-density lipoprotein [IDL], and low-density lipoprotein [LDL]) were
positively associated with risk of both diseases. In contrast, cholesterol in large and medium high-density lipoprotein (HDL) particles was inversely associated with
risk of MI and IS, whereas triglycerides in HDL particles were positively associated with disease risk. Neither lipoproteins nor lipid constituents showed associations
with risk of ICH. In contrast, glucose and the inﬂammation marker glycoprotein acetyls were both associated with higher risks of all 3 diseases. Thus, although lipids and
lipoproteins appear to be less relevant to ICH than MI or IS, the association of some metabolites with MI, IS, and ICH indicates shared pathways for all 3 subtypes of
vascular disease.
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629Consistent with previous observational studies
(6,20), we identiﬁed inverse associations of medium
and large HDL particles and cholesterol concentra-
tions within these lipoproteins with risk of MI.
Although this could be explained by residual con-
founding or reverse causality, we note that most ge-
netic investigations of HDL in CHD to date(16,17,21,22) have used genetic variants associated
with HDL-C overall, a composite measure of the sum
of cholesterol concentrations across HDL lipopro-
teins. The collective ﬁndings of the present and
recent studies (6,23) indicate that the inverse obser-
vational associations of cholesterol in HDL particles
are limited to large and medium subclasses. As such,
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630it is plausible that inclusion of genetic variants in
previous studies that associate disease risk with het-
erogeneous HDL particles (24) could mask a potential
“true” protective effect constrained to medium and
large HDL; however, medium and large HDL particles
make a substantial contribution to most measures of
circulating HDL-C.
One of the most striking ﬁndings from the present
study is the absence of association of any lipoprotein,
apolipoprotein, or lipid constituent with risk of ICH.
Although the observed associations differ from pre-
vious studies that reported inverse associations of
LDL-C with risk of ICH (5), our study suggests ICH is
possibly less driven by atherosclerosis and more so by
hypertension and frailty of blood vessels. However, a
modest correlation between the directions of associ-
ation for IS and ICH (Figure 4) indicates it is possible
that the individual null ﬁndings for ICH reﬂect a lack
of statistical power in the present study to detect
modest, but potentially real, associations of these
measures with ICH.
Several other non–lipid-related metabolic markers
did show strong associations with ICH. For
example, glucose traits and the inﬂammation
marker glycoprotein acetyls were similarly associ-
ated with risk of ICH as to risk of MI and IS.
Glycoprotein acetyls are a marker of glycosylated
proteins, acute-phase reactants present in very
small quantities in the blood (25–28). They are
moderately correlated with C-reactive protein (29)
and recent studies (6,30,31) reported elevated CVD
risks associated with higher concentrations of
glycoprotein acetyls, as in the present study. Other
studies have also shown glycoprotein acetyls to
associate with hypertension, plasma glucose (29),
and incident type 2 diabetes (32). To our knowl-
edge, the present study is the ﬁrst to quantify its
association with risk of incident ICH and demon-
strate consistent associations of glycoprotein acetyls
across MI, IS, and ICH.
The present study adds new knowledge to a
recent study in Europeans (6) by demonstrating
consistent associations of cholesterol and TG when
present in apolipoprotein B–containing lipoproteins,
yet differential associations of cholesterol and TG
when present in HDL lipoproteins. The present
study did not replicate the association of phenylal-
anine with risk of ischemic CVD (6), potentially
reﬂecting effect modiﬁcation by an environmental
exposure such as dietary factors (11). This study also
adds new information on the associations of these
metabolic markers with ICH.
Our study has several strengths. The availability of
8 traits measured by both NMR spectroscopy andaccredited clinical chemistry assays, and 137 dupli-
cate samples of NMR metabolomics, provides tests of
internal validity. This is one of the largest studies of
the relationship of blood-based metabolic markers
and risk of incident vascular disease subtypes. The
absence of drug treatment by statins or other lipid-
modifying drugs at the time of blood sampling, and
the incident nature of vascular cases, reduces sources
of potential bias. Analysis of 3 different diseases (MI,
IS, and ICH) in the same study facilitated direct
comparison of risk estimates of metabolic markers
with these diseases.
STUDY LIMITATIONS. The lack of associations of li-
poproteins and lipids with risk of ICH may reﬂect
low statistical power. The low mean levels of LDL-C
in the present study could challenge extrapolation
of our ﬁndings to Western populations; however,
the INTERHEART global study of risk factors for
acute myocardial infarction (33) found similar as-
sociations of lipoproteins with MI irrespective of
geographical region. The NMR spectroscopy assay
did not quantify lipoprotein(a), apolipoprotein CIII,
and HDL functionality, which would be interesting
additions to the present study. There is substantial
collinearity within the metabolomics data, with
multiple lipid measures representing subsets of
strongly correlated lipid factions. This can obscure
the interpretation of individual trait associations,
making it difﬁcult to clarify which lipoprotein
characteristic (concentration, particle size, lipid
constituent) accounts for disease associations.
Nevertheless, this does not detract from the insights
evident where there were clear differences in the
patterns of associations (e.g., when comparing small
and large HDL particles, or when comparing TG and
cholesterol in HDL particles).
CONCLUSIONS
Lipoproteins and lipids show generally consistent
associations with risks of MI and IS. The present
study demonstrated opposing associations of
cholesterol and TG in HDL particles with risk of MI
and IS. Although lipids and lipoproteins may play a
less important role in the development of ICH as
compared with MI or IS, inﬂammation may play a
role in MI, IS, and ICH. Large-scale studies using
genetic approaches are needed to clarify the causal
roles of individual lipoproteins, lipid constituents,
and other metabolic markers for subtypes of stroke
and MI.
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